Edition:
India

Abeona Therapeutics Inc (ABEO.OQ)

ABEO.OQ on NASDAQ Stock Exchange Capital Market

16.40USD
22 Jun 2018
Change (% chg)

$0.60 (+3.80%)
Prev Close
$15.80
Open
$15.80
Day's High
$16.40
Day's Low
$15.65
Volume
904,376
Avg. Vol
249,791
52-wk High
$22.70
52-wk Low
$5.30

Latest Key Developments (Source: Significant Developments)

Abeona Therapeutics Provides Clinical Update On MPS IIIA Gene Therapy Trial
Friday, 18 May 2018 

May 18 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS PROVIDES CLINICAL UPDATE ON MPS IIIA GENE THERAPY TRIAL AT THE 21ST ANNUAL ASGCT MEETING.ABEONA THERAPEUTICS- ABO-102 18-MONTH EFFICACY & SAFETY DATA CONTINUE TO DEMONSTRATE TIME- & DOSE-DEPENDENT REDUCTIONS IN UNDERLYING DISEASE PATHOLOGY.ABEONA THERAPEUTICS- RESULTS FROM PHASE 1/2 CLINICAL TRIAL FOR ABO-102 SHOW DURABLE BIOPHYSICAL REDUCTIONS OF DISEASE BURDEN.ABEONA THERAPEUTICS INC - ABO-102 IS WELL-TOLERATED IN ALL SUBJECTS TO DATE, WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS REPORTED.  Full Article

Abeona Therapeutics Posts Q1 Loss Of $0.18 Per Share
Friday, 11 May 2018 

May 11 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q1 LOSS PER SHARE $0.18.Q1 REVENUE $2.6 MILLION VERSUS $186,000.Q1 REVENUE VIEW $228,000 -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018 WERE $132 MILLION, COMPARED TO $137.8 MILLION AS OF DECEMBER 31, 2017.  Full Article

Abeona Announces FDA Grants Rmat Designation To ABO-102 Gene Therapy In MPS Iiia
Monday, 23 Apr 2018 

April 23 (Reuters) - Abeona Therapeutics Inc ::ABEONA ANNOUNCES FDA GRANTS RMAT DESIGNATION TO ABO-102 GENE THERAPY IN MPS IIIA.ABEONA THERAPEUTICS INC - COMPANY CONTINUES TO ENGAGE FDA ON ITS ONGOING PHASE 1/2 TRIAL.ABEONA - FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION TO ABO-102, CO'S GENE THERAPY FOR TREATMENT OF SANFILIPPO SYNDROME TYPE A.  Full Article

Abeona Q3 loss per share $0.13
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Abeona Therapeutics Inc :Abeona reports third quarter 2017 financial results and recent business highlights.Q3 loss per share $0.13.Q3 revenue $219,000 versus I/B/E/S view $220,000.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.  Full Article

Abeona Therapeutics prices offering of five million shares at $16 per share
Tuesday, 17 Oct 2017 

Oct 16 (Reuters) - Abeona Therapeutics Inc :Announces pricing of public offering of common stock.Pricing underwritten public offering of five million shares of common stock at a public offering price of $16.00 per share​.  Full Article

Abeona Therapeutics announces public offering of common stock
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Abeona Therapeutics Inc :Abeona Therapeutics announces public offering of common stock.  Full Article

Abeona Therapeutics to receive $13.85 mln of grants for development of Sanfilippo gene therapy programs​
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Abeona Therapeutics Inc :Abeona Therapeutics Inc - ‍nine global foundations collaborate to grant $13.85 million for continued advancement of lead Sanfilippo gene therapy programs​.  Full Article

Abeona Therapeutics enrolls first two patients in phase 1/2 clinical trial in MPS IIIA
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Abeona Therapeutics Inc : :Abeona Therapeutics enrolls first two patients in pivotal expansion of phase 1/2 clinical trial in MPS IIIA.Says to ‍report additional clinical data in ABO-102 global trial later this year​.  Full Article

Viking Global Investors reports 5.6 percent passive stake in Abeona Therapeutics
Tuesday, 3 Oct 2017 

Oct 2 (Reuters) - Abeona Therapeutics Inc :Viking Global Investors Lp reports 5.6 percent passive stake in Abeona Therapeutics Inc ‍​as of Sept 22 - SEC filing.  Full Article

Abeona Therapeutics Q2 loss per share $0.21
Tuesday, 15 Aug 2017 

Aug 15 (Reuters) - Abeona Therapeutics Inc :Abeona Therapeutics reports second quarter 2017 financial results and recent business highlights.Q2 loss per share $0.21.Q2 revenue $217,000 versus I/B/E/S view $230,000.Q2 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.  Full Article